EP1105528A4 - Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter - Google Patents

Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter

Info

Publication number
EP1105528A4
EP1105528A4 EP99935898A EP99935898A EP1105528A4 EP 1105528 A4 EP1105528 A4 EP 1105528A4 EP 99935898 A EP99935898 A EP 99935898A EP 99935898 A EP99935898 A EP 99935898A EP 1105528 A4 EP1105528 A4 EP 1105528A4
Authority
EP
European Patent Office
Prior art keywords
staging
diagnosing
imaging
monitoring
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99935898A
Other languages
German (de)
English (en)
Other versions
EP1105528A1 (fr
Inventor
Yongming Sun
Herve Recipon
Robert Cafferkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1105528A1 publication Critical patent/EP1105528A1/fr
Publication of EP1105528A4 publication Critical patent/EP1105528A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
EP99935898A 1998-08-04 1999-07-22 Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter Withdrawn EP1105528A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9523298P 1998-08-04 1998-08-04
PCT/US1999/016811 WO2000008210A1 (fr) 1998-08-04 1999-07-22 Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter
US95232P 2008-09-08

Publications (2)

Publication Number Publication Date
EP1105528A1 EP1105528A1 (fr) 2001-06-13
EP1105528A4 true EP1105528A4 (fr) 2002-09-04

Family

ID=22250828

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99935898A Withdrawn EP1105528A4 (fr) 1998-08-04 1999-07-22 Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter

Country Status (4)

Country Link
EP (1) EP1105528A4 (fr)
JP (1) JP3422776B2 (fr)
CA (1) CA2347906A1 (fr)
WO (1) WO2000008210A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
EP1728518A1 (fr) * 1998-09-23 2006-12-06 Diadexus, Inc. Procédé servant à diagnostiquer, contrôler, traiter des cancers gynécologiques et le cancer des testicules, à en prendre l'image et à en determiner le stade
WO2000016805A1 (fr) * 1998-09-23 2000-03-30 Diadexus Llc Procede servant a diagnostiquer, controler, traiter des cancers gynecologiques et le cancer des testicules, a en prendre l'image et a en determiner le stade
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6649342B1 (en) 1999-03-15 2003-11-18 Eos Biotechnology, Inc. Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US6316272B1 (en) 1999-03-15 2001-11-13 Eos Biotechnology, Inc. Methods of diagnosis of colorectal cancer and methods of screening for colorectal cancer modulators
AU3752700A (en) * 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
JP2003526342A (ja) * 1999-11-23 2003-09-09 ディアデクサス インコーポレーテッド 乳癌の診断、モニタニング、ステージング、イメージングおよび処置の新規方法
US6780586B1 (en) 1999-11-29 2004-08-24 Protein Design Labs, Inc. Methods of diagnosing breast cancer
CA2392510A1 (fr) 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US6566502B1 (en) 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
EP1158001B1 (fr) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs
WO2002032292A2 (fr) * 2000-10-18 2002-04-25 The Board Of Trustess Of The Leland Stanford Junior University Procedes pour la mise au point et l'utilisation d'agents diagnostiques et therapeutiques
US20020132255A1 (en) * 2000-11-20 2002-09-19 Susana Salceda Compositions and methods relating to breast specific genes and proteins
EP1407015A2 (fr) * 2000-11-22 2004-04-14 Diadexus, Inc. Compositions et methodes relatives a des genes et a des proteines specifiques du sein
WO2004067564A2 (fr) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions contre l'antgene cancereux liv-1 et leurs utilisations
US20070208514A1 (en) * 2003-04-23 2007-09-06 Hiroshi Yatsuhashi Method of Preparing Disease Prognosis Model, Disease Prognosis Prediction Method using this Model, Prognosis Prediction Device Based on this Model, and Program for Performing the Device and Storage Medium Wherein Said Program is Stored
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
JP2005230011A (ja) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
JP6105481B2 (ja) 2010-12-06 2017-03-29 シアトル ジェネティクス，インコーポレーテッド Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
WO2012142670A1 (fr) * 2011-04-20 2012-10-26 The University Of Queensland Agent de résonance magnétique nucléaire
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002559A1 (fr) * 1997-07-07 1999-01-21 Abbott Laboratories Reactifs et methodes utiles pour detecter des pathologies mammaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668267A (en) * 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
WO1998018945A1 (fr) * 1996-10-31 1998-05-07 Abbott Laboratories Reactifs et procedes pour le depistage de pathologies mammaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002559A1 (fr) * 1997-07-07 1999-01-21 Abbott Laboratories Reactifs et methodes utiles pour detecter des pathologies mammaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] ebi; 12 July 1995 (1995-07-12), HILLIER ET AL.: "The WashU-Merck EST project", XP002205120, Database accession no. h26328 *
DATABASE EMBL [online] ebi; 6 August 1995 (1995-08-06), HILLIER ET AL.: "The WashU-Merck EST project", XP002205119, Database accession no. r83119 *
See also references of WO0008210A1 *

Also Published As

Publication number Publication date
WO2000008210A1 (fr) 2000-02-17
CA2347906A1 (fr) 2000-02-17
EP1105528A1 (fr) 2001-06-13
JP2002522751A (ja) 2002-07-23
JP3422776B2 (ja) 2003-06-30

Similar Documents

Publication Publication Date Title
EP1105528A4 (fr) Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter
EP1239874A4 (fr) Methode de diagnostic, de controle, de stadification, d'imagerie et de traitement du cancer de la prostate
MXPA01008794A (es) Metodo para diagnosticar y verificar carcinomas de pecho malignos.
EP1082459A4 (fr) Technique de diagnostic, de suivi et de stadification du cancer du poumon
EP1267934A4 (fr) Nouvelle methode de diagnostic, de surveillance, de stadification, d'imagerie et de traitement du cancer du sein
IL142729A0 (en) Method for improved imaging and photodynamic therapy
EP1131095A4 (fr) Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate
EP1082695A4 (fr) Procede et systeme d'evaluation informatique d'un risque de cancer du sein
IL125210A0 (en) Computerized image-processing method
SG81261A1 (en) Method for treating heart failure
EP1104486A4 (fr) Nouveau procede de diagnostic, de surveillance, de classification par stades, d'imagerie et de traitement du cancer des poumons
EP1107798A4 (fr) Nouveau procede de diagnostic, de surveillance, de classification par stades, d'imagerie et de traitement du cancer du colon
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
GB9422836D0 (en) Monitoring malignant disease
GB2318734B (en) Methods of preventing breast cancer
AU2001251223A1 (en) Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1082460A4 (fr) Nouveau procede de diagnostic, de surveillance et de stadification du cancer de la prostate
EP1117833A4 (fr) Nouveau procede pour diagnostiquer, surveiller, etablir la stadification, obtenir des images et traiter des cancers gastro-intestinaux
EP1126877A4 (fr) Methode de diagnostic, de suivi, de classification par stade, de visualisation et de traitement de cancer de la prostate
AU2001271621A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
NO20014805L (no) Blandinger og fremgangsmater for behandling og diagnose av brystkreft
EP1227841A4 (fr) Nouveau procede permettant de diagnostiquer, surveiller, determiner le stade, imager et traiter un cancer
EP1169066A4 (fr) Nouveau procede pour diagnostiquer, controler, etablir le bilan d'extension, visualiser, et traiter des cancers gynecologiques
EP1250149A4 (fr) Nouvelle methode de diagnostic, de suivi, de stadification, d'imagerie et de traitement du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7C 12P 19/34 B, 7C 07H 21/04 B, 7G 01N 33/53 B, 7G 01N 33/574 B, 7C 07K 14/47 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020718

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20020723

17Q First examination report despatched

Effective date: 20040308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051116